Virginia Mason Medical Center, Seattle, Washington.
Center for Biomedical Statistics and Institute of Translational Health Sciences, University of Washington, Seattle, Washington.
J Urol. 2015 Sep;194(3):674-9. doi: 10.1016/j.juro.2015.04.109. Epub 2015 May 9.
Most prostate cancer active surveillance protocols recommend a confirmatory biopsy within 3 to 6 months of diagnosis. Transperineal template guided biopsy is an approach to improve the detection of high grade prostate cancer. However, to our knowledge the optimal technique is unknown. We evaluated the relative performance of 2 transperineal template guided biopsy approaches.
Institutional review board approved prospective databases at Virginia Mason and University of Michigan were used. Men eligible for active surveillance based on initial 12-core biopsy demonstrating NCCN® guideline low risk prostate cancer were included in study. All men underwent confirmatory transperineal template guided biopsy between 2005 and 2014, and within 6 months of diagnosis. The biopsy technique was based on a 24-core template with 12 anterior and 12 posterior cores or a template based on gland volume with an average of 1 core per cc. Outcome comparisons were made by the chi-square and Fisher exact tests, the Welch t-test and linear regression.
Of the 135 men 46 underwent 24-core biopsy and 89 underwent volume based biopsy (median 62 cores). No statistically significant difference was noted in the prevalence of upgrading (35% vs 29%, p = 0.64) or complications (9% vs 16%, p = 0.38) between the 24-core and volume based groups. The difference in the probability of upgrading by volume based biopsy adjusted for age, prostate specific antigen, prostate volume, clinical stage and number of prior biopsies was -4% (95% CI -24 to 14%, p = 0.63).
A significant difference was not detected in upgrading or morbidity between a 24-core template and a more exhaustive volume based template. A less invasive 24-core transperineal template guided biopsy strategy may suffice to accurately identify men who are appropriate for active surveillance.
大多数前列腺癌主动监测方案建议在诊断后 3 至 6 个月内进行确认性活检。经会阴模板引导活检是提高高级别前列腺癌检出率的一种方法。然而,据我们所知,最佳技术尚不清楚。我们评估了 2 种经会阴模板引导活检方法的相对性能。
使用弗吉尼亚梅森大学和密歇根大学的机构审查委员会批准的前瞻性数据库。符合条件的男性最初的 12 核活检显示 NCCN®指南低危前列腺癌,有资格进行主动监测。所有男性均于 2005 年至 2014 年期间在诊断后 6 个月内行经会阴模板引导确认性活检。活检技术基于 12 个前核心和 12 个后核心的 24 核模板或基于腺体体积的模板,平均每 cc 有 1 个核心。采用卡方检验和 Fisher 确切检验、Welch t 检验和线性回归进行结果比较。
在 135 名男性中,46 名男性接受了 24 核活检,89 名男性接受了基于体积的活检(中位数 62 核)。24 核组和基于体积组的升级(35%对 29%,p = 0.64)或并发症(9%对 16%,p = 0.38)发生率无统计学差异。基于体积的活检调整年龄、前列腺特异性抗原、前列腺体积、临床分期和先前活检次数后,升级概率差异为-4%(95%CI -24 至 14%,p = 0.63)。
在升级或发病率方面,24 核模板和更详尽的基于体积的模板之间没有发现显著差异。一种侵入性较小的 24 核经会阴模板引导活检策略可能足以准确识别适合主动监测的男性。